(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 14.7MM | +9% |
Operating Income | -6.9MM | -4% |
Operating Expenses | 21.5MM | +4% |
Net Income | -9.1MM | -17% |
R&D | 1.9MM | -3% |
G&A | 16.3MM | +5% |
Amortization | 483K | -3% |
Interest Expense | 2.3MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
LOUISVILLE, Colo., March 25, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.
Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript March 1, 2024 Biodesix, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.11. BDSX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. […]
Biodesix ( NASDAQ:BDSX ) Full Year 2023 Results Key Financial Results Revenue: US$49.1m (up 28% from FY 2022). Net...
Q4 2023 Biodesix Inc Earnings Call
Financial Highlights Reflect Continued Operational Efficiency and Market Expansion
LOUISVILLE, Colo., March 01, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).
LOUISVILLE, Colo., February 26, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the TD Cowen 44th Annual Health Care Conference, which will be held from March 4-6, 2024.
BOULDER, Colo., February 16, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day.
On February 12, 2024, Scott Hutton, President & CEO of Biodesix Inc (NASDAQ:BDSX), sold 64,390 shares of the company's stock, according to a recent SEC Filing.
Insiders were net buyers of Biodesix, Inc.'s ( NASDAQ:BDSX ) stock during the past year. That is, insiders bought more...